Greystone Associates Report Analyzes Clinical, Regulatory and Therapeutic Factors Driving Growth of Powerful New Drugs Based on the Human Immune Response
Get the full story...
Japan 's health authorities have approved Roche's cancer drug Herceptin for the treatment of HER2-positive breast cancer.
Get the full story...
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Get the full story...
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
Read the full story
Combining the molecularly targeted therapy Herceptin with chemotherapy in women with early stage breast cancer significantly improves disease-free survival for patients with a specific genetic mutation that results in very aggressive disease, a top UCLA researcher reported Thursday.
Read the full story
TEACH study is phase III trial of new targeted drug Tykerb for HER2-positive tumors
Read the full story
